Altus Capital Partners, Inc., an investment firm focusing on manufacturing businesses, has announced its recent acquisition of Tennessee-based ChoiceSpine, LP, a privately held spinal implant company that offers specialized spinal implants, instrumentation, and biologics for the surgical treatment of complex spine disorders.
Altus Capital Partners Acquires ChoiceSpine
1 min read Premium comments
#acquisitionSecondary#choicespine#altuscapitalpartners
ChoiceSpine collaborates with physicians to develop new products that incorporate current medical technology with customized patient solutions. ChoiceSpine products include minimally invasive, cervical, thoracolumbar, interbody, lateral, and biologics kits and implants.
Altus Co-Founder and Senior Partner Gregory L. Greenberg announced, “We recognize the need in the medical technology space for proven spinal products that can enhance the quality of life for spinal patients…. ChoiceSpine, a global medical device corporation specializing in innovative solutions for both spinal fusion hardware and biologics, demonstrates a track record of proven innovation, strong sales growth, increased distribution and the necessity of their products in the marketplace.”
OTWspoke with Marty Altshuler, Co-President of ChoiceSpine about the recent acquisition. Altshuler said, “This acquisition allows ChoiceSpine to continue growing with double digit growth as we have experienced in the last 10 years. This allows us to have a financial owner and partner that sees the value and opportunity in the spinal fusion market with a strong management team to continue doing what we have been doing in the last 12 years but with the addition of added resources we have not had before from growing organically.”
“The desire to continue growing with the goal of doubling our sales incorporating the best product technology and resources available in order to meet our five-year plan,” said Altshuler. “Our aggressive plan will include future acquisitions in products and technology that puts ChoiceSpine in the top tier of surgeon requests for their spinal fusion needs. Our focus will continue to be in degenerative spine with an increased effort in additive manufacturing while also looking to enter into other more complex spine and biologics initiatives.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.